Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy.
ECOG performance status
Immunotherapy
Venous thromboembolism
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
01
01
2021
accepted:
04
03
2021
pubmed:
13
3
2021
medline:
16
10
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in cancer patients. However, the association of VTE with immunotherapy remains poorly defined. We therefore evaluated the frequency of VTE in patients receiving immunotherapy and tried to determine predisposing factors. A total of 133 adult metastatic cancer patients treated with immunotherapy for any cancer between were included. Baseline demographics, ECOG performance status, type of tumors, and baseline blood count parameters were recorded. Possible predisposing factors were evaluated with univariate and multivariate analyses. The median age was 60 (interquartile range (IQR) 48-66) years, and the median follow-up was 10.1 (IQR 5.8-18.5) months. Renal cell carcinoma (26.3%) and melanoma (24.1%) were most common diagnoses. Fifteen patients (11.3%) had an episode of VTE. Most of the VTEs were diagnosed as pulmonary emboli (10/15; 67%). Eighty percent (12/15) of these VTE cases were detected incidentally. Patients with a baseline ECOG performance status of 1 or more (29.3% of patients) had a significantly increased risk of venous thrombosis (ECOG ≥1 vs. 0, HR: 3.023, 95% CI: 1.011-9.039, p=0.048). Other factors, including patient age, tumor type, body mass index, baseline thrombocyte, neutrophil, and lactate dehydrogenase levels were not significantly associated with VTE risk. In this study, we observed VTE development in more than 10% of immunotherapy-treated patients and increased VTE risk in patients with poorer ECOG status. With the asymptomatic nature of VTEs in most cases, a high index of suspicion level for VTE is required in patients treated with immunotherapy.
Identifiants
pubmed: 33709186
doi: 10.1007/s00520-021-06139-3
pii: 10.1007/s00520-021-06139-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5417-5423Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S et al (2019) Advances in cancer immunotherapy 2019 – latest trends. J Exp Clin Cancer Res 38:268. https://doi.org/10.1186/s13046-019-1266-0
doi: 10.1186/s13046-019-1266-0
pubmed: 31217020
pmcid: 31217020
Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL et al. (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-celllung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 387:1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265. https://doi.org/10.1016/S0140-6736(16)32517-X
doi: 10.1016/S0140-6736(16)32517-X
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356. https://doi.org/10.1056/NEJMoa1709684
doi: 10.1056/NEJMoa1709684
pubmed: 28889792
pmcid: 28889792
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813. https://doi.org/10.1056/NEJMoa1510665
doi: 10.1056/NEJMoa1510665
pubmed: 5719487
pmcid: 5719487
Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M et al (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395:1547–1557. https://doi.org/10.1016/s0140-6736(20)30230-0
doi: 10.1016/s0140-6736(20)30230-0
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC et al (2014) PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319. https://doi.org/10.1056/NEJMoa1411087
doi: 10.1056/NEJMoa1411087
pubmed: 4348009
pmcid: 4348009
Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin 70:86–104. https://doi.org/10.3322/caac.21596
doi: 10.3322/caac.21596
Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125:490–493. https://doi.org/10.1016/j.thromres.2009.12.023
doi: 10.1016/j.thromres.2009.12.023
pubmed: 2878879
pmcid: 2878879
Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6:401–410. https://doi.org/10.1016/s1470-2045(05)70207-2
doi: 10.1016/s1470-2045(05)70207-2
pubmed: 15925818
pmcid: 15925818
BLOM JW, Vanderschoot J, Oostindier M, Osanto S, Van Der Meer F et al (2006) Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost 4:529–535
doi: 10.1111/j.1538-7836.2006.01804.x
Roopkumar J, Kim AS, Bicky T, Hobbs BP, Khorana AA (2018) Venous thromboembolism in cancer patients receiving immunotherapy. Blood 132:2510–2510. https://doi.org/10.1182/blood-2018-99-116439
doi: 10.1182/blood-2018-99-116439
Sainz LG, Martínez-Marin V, Lozano DV, Pérez DM, Barbas JP et al (2019) Incidence of vascular thromboembolism events in cancer patients receiving immunotherapy: a single institution experience. Ann Oncol 30:v725
doi: 10.1093/annonc/mdz265.021
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8
doi: 10.1016/0021-9681(87)90171-8
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907. https://doi.org/10.1182/blood-2007-10-116327
doi: 10.1182/blood-2007-10-116327
pubmed: 18216292
pmcid: 18216292
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE (2017) What is polypharmacy? A systematic review of definitions. BMC Geriatr 17:230. https://doi.org/10.1186/s12877-017-0621-2
doi: 10.1186/s12877-017-0621-2
pubmed: 29017448
pmcid: 5635569
Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J et al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J 41:543–603. https://doi.org/10.1093/eurheartj/ehz405
doi: 10.1093/eurheartj/ehz405
pubmed: 31504429
pmcid: 31504429
Lutgens E, Seijkens TTP (2020) Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease. J Immunother Cancer 8:e000300. https://doi.org/10.1136/jitc-2019-000300
doi: 10.1136/jitc-2019-000300
pubmed: 32034065
pmcid: 32034065
Carmona-Bayonas A, Gómez D, Martínez de Castro E, Pérez Segura P, Muñoz Langa J et al (2020) A snapshot of cancer-associated thromboembolic disease in 2018-2019: first data from the TESEO prospective registry. Eur J Intern Med 78:41–49. https://doi.org/10.1016/j.ejim.2020.05.031
doi: 10.1016/j.ejim.2020.05.031
pubmed: 32482596
pmcid: 32482596
Giustozzi M, Curcio A, Weijs B, Field TS, Sudikas S et al (2020) Variation in the association between antineoplastic therapies and venous thromboembolism in patients with active cancer. Thromb Haemost 120:847–856. https://doi.org/10.1055/s-0040-1709527
doi: 10.1055/s-0040-1709527
Nichetti F, Ligorio F, Zattarin E, Signorelli D, Prelaj A et al (2019) Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients. Cancers (Basel) 12. https://doi.org/10.3390/cancers12010067
Nick van E, Marcello Di N, Gabriela C, Ankie K, Hans-Martin O et al (2017) Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 102:1494–1501. https://doi.org/10.3324/haematol.2017.169060
doi: 10.3324/haematol.2017.169060
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nature reviews. Clin Oncol 15:325–340. https://doi.org/10.1038/nrclinonc.2018.29
doi: 10.1038/nrclinonc.2018.29
Reardon DA, Nayak L, Peters KB, Clarke JL, Jordan JT, de Groot JF, Nghiemphu PL, Kaley TJ, Colman H, Gaffey SC, Caruso V, Bednarek Debruyne M, Bhavsar C, Molinaro AM, Smith T, Severgnini M, Wen PY (2018) Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. In. Proc Am Soc Clin Oncol 6:2006
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127. https://doi.org/10.1056/NEJMoa1816714
doi: 10.1056/NEJMoa1816714
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905. https://doi.org/10.1056/NEJMoa1915745
doi: 10.1056/NEJMoa1915745
pubmed: 32402160
pmcid: 32402160
Bach AG, Schmoll HJ, Beckel C, Behrmann C, Spielmann RP, Wienke A, Abbas J, Surov A (2014) Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events. Acta Radiol 55:45–53. https://doi.org/10.1177/0284185113491569
doi: 10.1177/0284185113491569
Bozas G, Jeffery N, Ramanujam-Venkatachala D, Avery G, Stephens A et al (2018) Prognostic assessment for patients with cancer and incidental pulmonary embolism. Thromb J 16:8. https://doi.org/10.1186/s12959-017-0157-x
doi: 10.1186/s12959-017-0157-x
pubmed: 5802055
pmcid: 5802055
Gutierrez-Sainz L, Martinez-Marin V, Viñal D, Martinez-Perez D, Pedregosa J et al (2020) Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. Clin Transl Oncol. https://doi.org/10.1007/s12094-020-02515-3
Guven DC, Sahin TK, Aksun MS, Taban H, Aktepe OH et al (2020) Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Support Care Cancer. https://doi.org/10.1007/s00520-020-05702-8
Cooksley T, Gupta A, Al-Sayed T, Lorigan P (2020) Emergency presentations in patients treated with immune checkpoint inhibitors. Eur J Cancer 130:193–197. https://doi.org/10.1016/j.ejca.2020.02.025
doi: 10.1016/j.ejca.2020.02.025
pubmed: 32224417
pmcid: 32224417
Scotté F, Leroy P, Chastenet M, Aumont L, Benatar V et al (2019) Treatment and prevention of cancer-associated thrombosis in frail patients: tailored management. Cancers 11:48. https://doi.org/10.3390/cancers11010048
doi: 10.3390/cancers11010048
Metcalf RL, Fry DJ, Swindell R, McGurk A, Clamp AR et al (2014) Thrombosis in ovarian cancer: a case control study. Br J Cancer 110:1118–1124. https://doi.org/10.1038/bjc.2014.3
doi: 10.1038/bjc.2014.3
pubmed: 24448364
pmcid: 24448364
Ferroni P, Riondino S, Formica V, Cereda V, Tosetto L et al (2015) Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. Int J Cancer 136:1234–1240. https://doi.org/10.1002/ijc.29076
doi: 10.1002/ijc.29076
pubmed: 25042739
pmcid: 25042739
Carmona-Bayonas A, Jiménez-Fonseca P, Font C, Fenoy F, Otero R et al (2017) Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. Br J Cancer 116:994–1001. https://doi.org/10.1038/bjc.2017.48
doi: 10.1038/bjc.2017.48
pubmed: 28267709
pmcid: 28267709